$AVR

L1 Capital Pty Ltd purchased $2.0M of AVR (indirect holdings)

L1 Capital Pty Ltd purchased 272,695 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at $7.18 ($1.96M total) on 2026-10-06.

Original reporting
SEC EDGAR · L1 Capital Pty Ltd
Published Oct 8, 2026, 11:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 11:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AVR
Neutral
medium confidence
Mentioned
$AVR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

A disclosed open-market purchase by a significant holder can influence sentiment, but without accompanying company fundamentals, it is more useful for positioning and monitoring than for a standalone trade catalyst.

02

Market read

Traders may treat the $1.96M indirect accumulation as a mild sentiment input, but it is unlikely to drive a major repricing absent other news.

03

What to watch

No 10b5-1 plan is cited, but the filing does not explain intent, whether the buyer is affiliated, or whether other holders are acting similarly, which can dilute the interpretability for traders.

Relevance 7/10Novelty 6/10Timing: filed 2026-10-08, transaction dated 2026-10-06

Background

The article is an SEC Form 4 insider transaction disclosure for Anteris Technologies Global Corp. (AVR).

Company-level read

Ticker impact

$AVRNeutralMedium confidence
Context

L1 Capital Pty Ltd, a 10% owner, bought 272,695 shares of Anteris Technologies Global Corp. at $7.1800 on 2026-10-06 via an indirect open-market purchase.

Expected impact

Likely modest support or neutral read-through as the market weighs ownership/indirect structure rather than expecting immediate fundamentals change.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure with a clear buy size (~$2.0M), but it is an indirect holding by a 10% owner and lacks additional catalysts like guidance, contracts, or operational updates.

Market effects

Limited sector read-through; this is company-specific ownership activity without disclosed operational or regulatory developments.

None indicated.

None indicated.

Counterpoint

Indirect purchases by a 10% owner can reflect portfolio rebalancing, tax/structuring, or pre-existing arrangements, so the signal may be weaker than it appears.

Key entities

  • Anteris Technologies Global Corp.

    Subject of the Form 4 insider transaction disclosure (ticker AVR).

  • L1 Capital Pty Ltd

    Reported indirect open-market purchase of 272,695 shares on 2026-10-06.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AVRMedAI 8/10

Small Cap watch: ASX small caps ease after strong week as NewPeak, Orthocell and Anteris advance drilling, sales and data

The S&P/ASX Small Ordinaries Index fell 0.74% on Friday but gained 3.03% over the week. NewPeak Metals completed drilling in Argentina, Orthocell reported record US sales, and Anteris Technologies released positive heart valve data. NewPeak tested gold mineralization, Orthocell sold 92 units of Remplir, and Anteris' valve showed improved haemodynamics in 22 patients.

$AVRMedAI 8/10

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

Anteris Technologies (NASDAQ: AVR, ASX: AVR) reported 30-day outcomes for its DurAVR THV in 22 patients with medium aortic annuli, showing positive hemodynamic and safety results. The DurAVR THV is being evaluated in the ongoing PARADIGM trial, a global study comparing it to commercially available TAVRs. The company aims to confirm the valve's effectiveness in a randomized setting.

$AVRMedAI 8/10

Anteris Technologies secures German clearance to expand PARADIGM heart valve trial

Anteris Technologies (ASX:AVR, NASDAQ:AVR) received German regulatory approval to expand its PARADIGM heart valve trial, allowing patient recruitment in Europe's largest market. The trial aims to enroll 1,000 patients to evaluate the DurAVR valve against existing devices. The company expects Germany's expertise to accelerate enrollment. DurAVR is a transcatheter heart valve designed to mimic a healthy aortic valve.